PTK2B and diffuse large B-cell lymphoma: Our study has significant limitations, including the absence of a large validation dataset, the bioinformatics-based analyses being used without additional supportive laboratory testing of ERBB1 mRNA levels using other methods (e.g., quantitative RT-PCR, RNA sequencing), and a lack of data to show MLC from EGFR/ERBB1high DLBCL patients with amplified ERBB1 protein expression and PTK activity.